Search results
Chronic Lymphocytic Leukemia: Slow-Appearing Symptoms
Verywell Health via Yahoo News· 10 months agoNew therapies are transforming treatment Halfpoint Images / Getty Images Medically reviewed by...
What Is Leukemia?
Verywell Health via Yahoo News· 1 year agoLeukemia is a form of blood cancer that starts in your bone marrow, the spongy tissue inside your bones. It occurs when abnormal cells grow too fast and...
How this 12-year-old boy from Georgetown is helping lead the fight against cancer
Austin American-Statesman via Yahoo News· 1 year agoWhen Jaron Rodriguez was 23 months old, his mom Jessica Rodriguez noticed something didn't look...
Why Cellectis' Shares Rose 22.7% This Week
Motley Fool· 2 years agoShares of Cellectics (NASDAQ: CLLS), a clinical-stage biopharmaceutical company that specializes in oncology, rose 22.7% this week, according to data...
Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why
Zacks via Yahoo Finance· 4 months agoSana Bio (SANA) rallies 105% after the company reports encouraging pipeline progress with its...
Is It Too Late to Buy CRISPR Stock?
Motley Fool· 1 year agoCRISPR Therapeutics (NASDAQ: CRSP) has been a volatile stock over the past couple of years. Lately, the gene-editing company's shares have been trading...
3 AI Drug Discovery Stocks to Watch
Motley Fool· 8 months agoThe potential for artificial intelligence (AI) to be used as a tool for better drug discovery is already obvious. AI can help in patient recruitment,...
Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday?
Benzinga via Yahoo Finance· 1 month agoOn Monday, Vincerx Pharma Inc (NASDAQ:VINC) presented preliminary Phase 1 data for VIP236 and...
Biomea (BMEA) Up 99% on Upbeat Data From Type II Diabetes Study
Zacks via Yahoo Finance· 1 year agoPreliminary data from an ongoing mid-stage study shows that treatment with Biomea's (BMEA) lead...
Where Will CRISPR Therapeutics Be in 10 Years?
Motley Fool· 11 months agoConsider CRISPR Therapeutics (NASDAQ: CRSP), which is trading for around $61 a share, down from its high of $220.20 on Jan. 15, 2021. The company is on...
